Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Targeted drug therapies have greatly improved outcomes for patients with relapsed or
refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. However,
single drug therapies have limitations, therefore, the current study is evaluating a novel
oral combination of targeted drugs as a way of overcoming these limitations. This study will
determine the efficacy of the triple combination therapy, DTRM-555, in patients with R/R CLL
or R/R non-Hodgkin's lymphoma.